<DOC>
	<DOCNO>NCT00290355</DOCNO>
	<brief_summary>Patients receive injection GSK 249553 vaccine . Appropriate test perform assess safety treatment ability induce immune response .</brief_summary>
	<brief_title>Study Test Efficacy Vaccine GSK 249553 Treating Non-small-cell Lung Cancer After Tumour Removal Surgery</brief_title>
	<detailed_description>This Phase IIb study conduct centre several European country accord multicentre , international , randomise , double-blind design . It provide information clinical immunological efficacy tolerability GSK 249553 administer patient stage IB , II NSCLC . The study treatment administer intramuscular injection ; first administration take place 4-6 week surgery . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Written inform consent obtain prior surgical tumour resection prior performance protocolspecific procedure . At least 18 year age time resection . Pathologically proven , surgically stag squamous nonsquamous IB , IIA IIB NSCLC , complete surgical resection . The operative technique resection patient 's tumour involves least lobectomy sleeve lobectomy , conform follow criterion : 1 . Removal gross disease negative resection margin , lobectomy , sleeve resection , bilobectomy pneumonectomy , base intraoperative finding . 2 . The level nodal sample least follow : Levels 4 , 7 , 10 right upper right middle lobes Levels 4 , 7 , 9 , 10 right low lobe Levels 5 , 6 , 7 leave upper lobe Levels 7 , 9 , 10 leave low lobe . maximum define systematic radical mediastinal lymphadenectomy : ipsilateral easily accessible lymphnode level must remove , independently location primary tumour . The level nodal sampling follow : Levels 2 , 4 , 7 , 8 , 9 , 10 rightsided tumour , Levels 5 , 6 , 7 , 8 , 9 , 10 leftsided tumour Tumour show expression MAGE3 antigen . Recovered surgery least 4 week 6 week . ECOG performance status ≤ 1 time randomisation . Laboratory criterion ( follow must fulfil ) : adequate bone marrow reserve , adequate renal function , adequate hepatic function , serum bilirubin within normal range , negative HIV antibody test , negative HBV antigen test , negative HCV antibody test . ( For female ) : EITHER childbearing potential OR sexually abstinent OR follow : negative urine/serum βHCG pregnancy test , use adequate contraceptive precaution 30 day first vaccination . Agree continue precaution 2 month completion course vaccination . Received anticancer specific treatment include radiotherapy , prior surgery , unless treatment previous malignancy allow protocol , i.e. , basal localise squamouscell skin carcinoma successfully treat , carcinoma situ cervix ( see exclusion criterion . 10 ) . Candidate postsurgery radiation therapy kind anticancerspecific treatment . Pregnant/lactating . ( For female patient childbearing potential ) : agree practice effective method contraception . Uncontrolled bleed disorder . Autoimmune disease . History anaphylaxis severe allergic reaction . Undergone splenectomy radiation spleen . Received major organ allograft . Malignancies sit ( except ( ) basal localise squamouscell skin carcinoma successfully treat , ( ii ) carcinoma situ cervix ) . Concurrent severe medical problem , unrelated malignancy , would significantly limit full compliance study expose patient unacceptable risk . Uncontrolled congestive heart failure hypertension . Unstable heart disease uncontrolled arrhythmia time enrolment . Psychiatric addictive disorder may compromise ability give informed consent , comply trial procedure . Any evidence residual tumour surgery . Require concomitant treatment systemic corticosteroid , immunosuppressive agent . Received chemotherapy , immunotherapy relate NSCLC . Need home oxygenation . Received investigational nonregistered drug vaccine study vaccine within 30 day precede first dose study vaccine , plan receive drug study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>